文献速递产科生殖医学母胎医学

厘清子宫内膜异位症、子宫腺肌症及辅助生殖技术相关因素对母体、胎盘、胎儿及新生儿不良结局的独立影响:系统综述与Meta分析结果

Untangling the independent effect of endometriosis, adenomyosis, and ART-related factors on maternal, placental, fetal, and neonatal adverse outcomes: results from a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2024-01-01

该系统综述与Meta分析检索截至2024年3月1日的文献,评估子宫内膜异位症、子宫腺肌症及辅助生殖技术(ART)相关因素对不良妊娠结局的独立影响。子宫内膜异位症与前置胎盘、早产及剖宫产风险升高相关,子宫腺肌症与流产及子痫前期相关,囊胚移植、冻胚移植及人工周期冻胚移植与多种不良结局相关。作者建议对严重子宫内膜异位症患者避免叠加其他高风险暴露因素。

要点

  • 子宫内膜异位症患者前置胎盘风险升高(34项研究,OR 2.84;95%CI 2.47-3.26;I²=83%,中等质量)。
  • 子宫腺肌症与流产(14项研究,OR 1.83;95%CI 1.53-2.18;I²=72%,低质量)及子痫前期(7项研究,OR 1.70;95%CI 1.16-2.48;I²=77%,低质量)相关。
  • 人工周期冻胚移植与子痫前期(12项研究,OR 2.14;95%CI 1.91-2.39;I²=9%,低质量)及产后出血(6项研究,OR 2.43;95%CI 2.11-2.81;I²=15%,极低质量)相关。

核心结论

  • 严重子宫内膜异位症(rASRM III-IV期、深部子宫内膜异位症)是前置胎盘和早产的重要风险因素。
  • 作者建议不要在严重子宫内膜异位症基础上叠加其他与相同或不同产科不良结局强相关的暴露因素。
  • 作者强烈建议不要对排卵且患有rASRM III-IV期子宫内膜异位症或深部子宫内膜异位症的女性使用人工周期方案进行冻胚移植。
  • 作者建议对该高风险人群进行单囊胚移植。

研究设计与样本

  • 系统综述与Meta分析,纳入随机对照试验、队列研究和病例对照研究。
  • 检索PubMed、MEDLINE、ClinicalTrials.gov、Embase和Scopus,截至2024年3月1日。
  • 遵循PRISMA和MOOSE报告指南,使用GRADE方法评估证据质量。
  • 注册号CRD42023401428。

主要发现

  • 子宫内膜异位症与前置胎盘风险升高相关(34项研究,OR 2.84;95%CI 2.47-3.26;I²=83%,中等质量),无论受孕方式,在rASRM III-IV期(OR 6.61;95%CI 2.08-20.98;I²=66%)和深部子宫内膜异位症(OR 14.54;95%CI 3.67-57.67;I²=54%)中关联更强。
  • 子宫内膜异位症与早产(43项研究,OR 1.43;95%CI 1.32-1.56;I²=89%,低质量)及剖宫产(29项研究,OR 1.52;95%CI 1.41-1.63;I²=93%,低质量)相关,无论受孕方式。
  • 子宫腺肌症与流产(14项研究,OR 1.83;95%CI 1.53-2.18;I²=72%,低质量)及子痫前期(7项研究,OR 1.70;95%CI 1.16-2.48;I²=77%,低质量)相关,在主分析和仅纳入ART妊娠的亚组分析中均存在。
  • 囊胚期胚胎移植与单卵双胎相关(28项研究,OR 2.05;95%CI 1.72-2.45;I²=72%,低质量)。
  • 冻胚移植与小于胎龄儿风险降低(21项研究,OR 0.59;95%CI 0.57-0.61;P<0.00001;I²=17%,极低质量)及大于胎龄儿风险升高(16项研究,OR 1.70;95%CI 1.60-1.80;P<0.00001;I²=55%,极低质量)相关。

关键数值与推荐

  • 子宫内膜异位症与前置胎盘:34项研究,OR 2.84(95%CI 2.47-3.26),I²=83%,中等质量证据。
  • 子宫内膜异位症与早产:43项研究,OR 1.43(95%CI 1.32-1.56),I²=89%,低质量证据。
  • 子宫腺肌症与流产:14项研究,OR 1.83(95%CI 1.53-2.18),I²=72%,低质量证据。
  • 人工周期冻胚移植与子痫前期:12项研究,OR 2.14(95%CI 1.91-2.39),I²=9%,低质量证据。
  • 人工周期冻胚移植与产后出血:6项研究,OR 2.43(95%CI 2.11-2.81),I²=15%,极低质量证据。

临床怎么用

  • 作者建议不要对排卵且患有rASRM III-IV期子宫内膜异位症或深部子宫内膜异位症的女性使用人工周期方案进行冻胚移植。
  • 作者建议对该高风险人群进行单囊胚移植。
  • 作者建议避免在严重子宫内膜异位症基础上叠加其他与相同或不同产科不良结局强相关的暴露因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with endometriosis may constitute a group at a particularly increased risk of pregnancy-related complications. Furthermore, women selected for assisted reproductive technology (ART) are exposed to additional endocrinological and embryological factors that have been associated with adverse pregnancy outcomes. OBJECTIVE AND RATIONALE: This study aimed to investigate the independent effect of endometriosis, adenomyosis, and various ART-related factors on adverse maternal, placental, fetal, and neonatal outcomes. SEARCH METHODS: Published randomized controlled trials, cohort studies, and case-control studies were considered eligible. PubMed, MEDLINE, ClinicalTrials.gov, Embase, and Scopus were systematically searched up to 1 March 2024. This systematic review and meta-analysis was performed in line with the PRISMA and the MOOSE reporting guidelines. To thoroughly investigate the association between endometriosis/adenomyosis and adverse pregnancy outcomes, sub-analyses were conducted, whenever possible, according to: the method of conception (i.e. ART and non-ART conception), the endometriosis stage/phenotype, the coexistence of endometriosis and adenomyosis, any pre-pregnancy surgical treatment of endometriosis, and the form of adenomyosis. The odds ratio (OR) with 95% CI was used as effect measure. The quality of evidence was assessed using the GRADE approach. OUTCOMES: We showed a higher risk of placenta previa in women with endometriosis compared to controls (34 studies, OR 2.84; 95% CI: 2.47, 3.26; I2 = 83%, moderate quality). The association was observed regardless of the method of conception and was particularly strong in the most severe forms of endometriosis (i.e. rASRM stage III-IV endometriosis and deep endometriosis (DE)) (OR 6.61; 95% CI: 2.08, 20.98; I2 = 66% and OR 14.54; 95% CI: 3.67, 57.67; I2 = 54%, respectively). We also showed an association, regardless of the method of conception, between endometriosis and: (i) preterm birth (PTB) (43 studies, OR 1.43; 95% CI: 1.32, 1.56; I2 = 89%, low quality) and (ii) cesarean section (29 studies, OR 1.52; 95% CI: 1.41, 1.63; I2 = 93%, low quality). The most severe forms of endometriosis were strongly associated with PTB. Two outcomes were associated with adenomyosis both in the main analysis and in the sub-analysis that included only ART pregnancies: (i) miscarriage (14 studies, OR 1.83; 95% CI: 1.53, 2.18; I2 = 72%, low quality) and (ii) pre-eclampsia (7 studies, OR 1.70; 95% CI: 1.16, 2.48; I2 = 77%, low quality). Regarding ART-related factors, the following associations were observed in the main analysis and confirmed in all sub-analyses conducted by pooling only risk estimates adjusted for covariates: (i) blastocyst stage embryo transfer (ET) and monozygotic twinning (28 studies, OR 2.05; 95% CI, 1.72, 2.45; I2 = 72%, low quality), (ii) frozen embryo transfer (FET) and (reduced risk of) small for gestational age (21 studies, OR 0.59; 95% CI, 0.57, 0.61; P < 0.00001; I2 = 17%, very low quality) and (increased risk of) large for gestational age (16 studies, OR 1.70; 95% CI, 1.60, 1.80; P < 0.00001; I2 = 55%, very low quality), (iii) artificial cycle (AC)-FET and pre-eclampsia (12 studies, OR 2.14; 95% CI: 1.91-2.39; I2 = 9%, low quality), PTB (21 studies, OR 1.24; 95% CI 1.15, 1.34; P < 0.0001; I2 = 50%, low quality), cesarean section (15 studies, OR 1.59; 95% CI 1.49, 1.70; P < 0.00001; I2 = 67%, very low quality) and post-partum hemorrhage (6 studies, OR 2.43; 95% CI 2.11, 2.81; P < 0.00001; I2 = 15%, very low quality). WIDER IMPLICATIONS: Severe endometriosis (i.e. rASRM stage III-IV endometriosis, DE) constitutes a considerable risk factor for placenta previa and PTB. Herein, we recommend against superimposing on this condition other exposure factors that have a strong association with the same obstetric adverse outcome or with different outcomes which, if coexisting, could determine the onset of an ominous obstetric syndrome. Specifically, we strongly discourage the use of AC regimens for FET in ovulatory women with rASRM stage III-IV endometriosis or DE. We also recommend single ET at the blastocyst stage in this high-risk population. REGISTRATION NUMBER: CRD42023401428.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Busnelli A, Di Simone N, Somigliana E, et al. Untangling the independent effect of endometriosis, adenomyosis, and ART-related factors on maternal, placental, fetal, and neonatal adverse outcomes: results from a systematic review and meta-analysis. Hum Reprod Update. 2024. PMID: 39049473. doi:10.1093/humupd/dmae024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。